Essity integrates BSN medical India into its fold

Mumbai: Leading global health and hygiene company, Essity, announced the final step in integrating BSN medical India into the Essity organization. Following the global acquisition of BSN medical in April 2017, the business in India continues its journey as Essity India, with a sharp focus on the medical and healthcare solutions market.

Emerging markets, including India, accounted for 35% of Essity’s global net sales in 2018. Essity India, aims to further strengthen its market position across three key portfolios: orthopedics, wound care and compression therapy.

  • Orthopedics: Solutions for fracture management, physiotherapy, orthopedic soft goods and braces
  • Woundcare: Solutions for acute and advanced wound care like surgical tapes, retention bandages, surgical/post-operation dressings, adhesive bandages/plasters
  • Compression therapy: Phlebology and lymphology solutions like compression bandages, compression stockings, pneumatic compression pumps, etc.

The three portfolios include heritage brands such as Delta-Cast, Actimove, Leukoplast, Cutimed and JOBST.

Speaking on this final step in the integration and launch of Essity India, Mr. Neeraj Raghuvanshi, Managing Director, Essity India said, “We are pleased to bring the global heritage of Essity to India. Our goal for the next two years is to strengthen the existing business and attain strong growth for the company. With our integrated therapy solutions, backed by cutting edge technology, we hope to positively contribute to the healthcare needs of Indian patients.”

In India, Essity will also work towards its global commitment to six key United Nations Sustainable Development Goals (UN SDGs), namely – Good health and well-being, Gender equality, Clean water and sanitation, Responsible consumption and production, Climate action and Life on land.

Mr. Carl-Magnus Stensson, Vice President Sales & Marketing, Asia Pacific – Health and Medical Solutions, Essity said, “Through our business operations, domain expertise and partnerships with others who share the same challenges and opportunities, we continuously work towards creating synergies that contribute to the achievement of the UN SDGs.”

“Sustainability is at the core of everything we do, and we hope to continue developing solutions through a sustainable approach. In India, our state-of-the-art manufacturing facilities in Goa, cater to the supply requirements of close to 60 countries, spanning across Asia-Pacific, Latin America and Africa. With the current expansion of our global legacy brands such as Leukoplast, Gypsona, Leukocrepe and the growing medical and healthcare needs of India, the country will continue to be a key regional business hub for Essity,” Mr.Stensson added.

Recently, Essity was recognized in The Sustainability Yearbook 2019 for the Household Product industry and received the Gold Class and Industry Mover distinction for excellent sustainability performance, by RobecoSAM’s ranking.

RobecoSAM is an investment specialist focused exclusively on Sustainability Investing and annually assesses the world’s largest companies for the Dow Jones Sustainability Index (DJSI), one of the world’s most prestigious sustainability indices.

The company’s India headquarters are located in Mumbai with an employee base of more than 200 people.

Related Posts

  • Health
  • April 14, 2025
  • 215 views
2025 Foundation Day of Sir Ganga Ram Hospital turned ‘Landmark’ Event

CM Rekha Gupta crossed quite a ‘Line’ to help SGRH expand in Delhi New Delhi : The Foundation Day (April 13) of Sir Ganga Ram Hospital is a landmark event…

‘Made in India’ Stents win major victory against Import Lobby

New Delhi/ Ahmadabad: Gujarat’s Department of Health and Family welfare beat a hasty retreat on its biased order against domestic stent makers, thanks to immediate intervention of former Union Health…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CEO speaks: India’s AI-Powered Pharma Revolution: The Next Big Wave in Healthcare

CEO speaks: India’s AI-Powered Pharma Revolution: The Next Big Wave in Healthcare

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals renamed as Cohance Lifesciences

Dabur misses estimates, profit drops 8% to Rs 320 crore

Dabur misses estimates, profit drops 8% to Rs 320 crore

Russian govt to take additional measures to avoid drug shortages

Russian govt to take additional measures to avoid drug shortages